Technical Analysis for ERNA - Eterna Therapeutics Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 1.79 | 3.12% | 0.05 |
ERNA closed up 3.12 percent on Friday, April 26, 2024, on 1.76 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: May 6
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Bullish Engulfing | Bullish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New Downtrend | Bearish | 3.12% | |
| Hammer Candlestick | Bullish | 3.12% | |
| NR7 | Range Contraction | 3.12% | |
| Narrow Range Bar | Range Contraction | 3.12% |
| Alert | Time |
|---|---|
| Outside Day | about 6 hours ago |
| Down 5% | about 6 hours ago |
| Down 3% | about 6 hours ago |
| Fell Below Previous Day's Low | about 6 hours ago |
| Down 2 % | about 6 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/06/2024
Eterna is focused on developing advanced therapies using state-of-the-art mRNA cell engineering technology. Its mission is to realize the potential of cell engineering to provide patients with transformational new medicines. The Company has in-licensed a portfolio of over 100 patents covering key cell engineering technologies, including what it believes are the most widely used methods for therapeutic gene editing currently in clinical development. Eterna has multiple next-generation cell and gene-editing therapies in preclinical development for various indications.
Sector: Consumer Cyclical
Industry: Broadcasting - TV
Keywords: Cancer Clinical Medicine Immunology Immune System Immunotherapy Natural Killer Cell T Cell Dendritic Cell
Classification
Sector: Consumer Cyclical
Industry: Broadcasting - TV
Keywords: Cancer Clinical Medicine Immunology Immune System Immunotherapy Natural Killer Cell T Cell Dendritic Cell
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.4 |
| 52 Week Low | 0.8401 |
| Average Volume | 8,563 |
| 200-Day Moving Average | 1.95 |
| 50-Day Moving Average | 1.99 |
| 20-Day Moving Average | 2.14 |
| 10-Day Moving Average | 2.01 |
| Average True Range | 0.16 |
| RSI (14) | 34.64 |
| ADX | 24.06 |
| +DI | 28.50 |
| -DI | 23.04 |
| Chandelier Exit (Long, 3 ATRs) | 2.02 |
| Chandelier Exit (Short, 3 ATRs) | 2.18 |
| Upper Bollinger Bands | 2.52 |
| Lower Bollinger Band | 1.77 |
| Percent B (%b) | 0.03 |
| BandWidth | 34.97 |
| MACD Line | -0.06 |
| MACD Signal Line | 0.00 |
| MACD Histogram | -0.0692 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.03 | ||||
| Resistance 3 (R3) | 2.04 | 1.96 | 1.99 | ||
| Resistance 2 (R2) | 1.96 | 1.90 | 1.96 | 1.98 | |
| Resistance 1 (R1) | 1.88 | 1.86 | 1.92 | 1.87 | 1.96 |
| Pivot Point | 1.80 | 1.80 | 1.82 | 1.80 | 1.80 |
| Support 1 (S1) | 1.72 | 1.74 | 1.76 | 1.71 | 1.62 |
| Support 2 (S2) | 1.64 | 1.70 | 1.64 | 1.60 | |
| Support 3 (S3) | 1.56 | 1.64 | 1.59 | ||
| Support 4 (S4) | 1.55 |
